Millendo Therapeutics to Present at the Stifel 2019 Healthcare Conference
ANN ARBOR, Mich.--(BUSINESS WIRE)--Nov 11, 2019--
Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 9:45 a.m. EST.
A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191111005071/en/
CONTACT: Millendo Investor Contact:
Stern Investor Relations
Millendo Media Contact:
KEYWORD: MICHIGAN NEW YORK UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: Millendo Therapeutics
Copyright Business Wire 2019.
PUB: 11/11/2019 08:30 AM/DISC: 11/11/2019 08:30 AM